Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.
Saved in:
| Title: | Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis. |
|---|---|
| Authors: | Nikolaou A; Modelling and Simulation, Evidera, London, UK., Ambavane A; Modelling and Simulation, Evidera, Waltham, MA, USA., Shah A; Modelling and Simulation, Evidera, Waltham, MA, USA., Ma W; Modelling and Simulation, Evidera, Waltham, MA, USA., Tosh J; Modelling and Simulation, Evidera, London, UK., Kapetanakis V; Modelling and Simulation, Evidera, London, UK., Willson J; GlaxoSmithKline, Upper Providence, PA, USA., Wang F; GlaxoSmithKline, Upper Providence, PA, USA., Hogea C; GlaxoSmithKline, Philadelphia, PA, USA., Gorsh B; GlaxoSmithKline, Philadelphia, PA, USA., Gutierrez B; GlaxoSmithKline, Philadelphia, PA, USA., Sapra S; GlaxoSmithKline, Philadelphia, PA, USA., Suvannasankha A; Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, IN, USA., Samyshkin Y; GlaxoSmithKline, Brentford, Middlesex, UK. |
| Source: | Expert review of hematology [Expert Rev Hematol] 2021 Dec; Vol. 14 (12), pp. 1137-1145. Date of Electronic Publication: 2021 Sep 20. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101485942 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1747-4094 (Electronic) Linking ISSN: 17474094 NLM ISO Abbreviation: Expert Rev Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1747-4094 |
|---|---|
| DOI: | 10.1080/17474086.2021.1970522 |
